Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors
American Society of Clinical Oncology Educational Book · 2023
DOI: 10.1200/edbk_404770 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2023. Verfasst von Mohamed A Gouda und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Glioma. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
The recent US Food and Drug Administration (FDA) approval of the dabrafenib/trametinib combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the result of more than 20 years of extensive research into BRAF mutations in human cancer, the underlying biological mechanisms that drive BRAF-mediated tumor growth, and the clinical testing and refinement of selective RAF and MEK kinase inhibitors. Such approval marks a significant achievement in the field of oncology and represents a major step forward in our ability to treat cancer. Early evidence supported the use of dabrafenib/trametinib combination in melanoma, non–small-cell lung cancer, and anaplastic thyroid cancer. Furthermore, data from basket trials have demonstrated consistently good response rates in various tumors, including biliary tract cancer, low-grade glioma, high-grade glioma, hairy cell leukemia, and multiple other malignancies, which has been the basis for FDA approval of a tissue-agnostic indication in adult and pediatric patients with BRAF V600E–positive solid tumors. From a clinical standpoint, our review delves into the efficacy of the dabrafenib/trametinib combination for BRAF V600E–positive tumors: examining the underlying rationale for its use, evaluating the latest evidence on its potential benefits, and discussing the possible associated adverse effects and strategies to minimize their impact. Additionally, we explore potential resistance mechanisms and future landscape of BRAF-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Shebin Al-Kom, Egypt.
- Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
- MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Mohamed A Gouda, Vivek Subbiah
Zitieren
APA
Gouda, M. A., & Subbiah, V. (2023). Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_404770
Vancouver
Gouda MA, Subbiah V. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors. American Society of Clinical Oncology Educational Book. 2023. doi:10.1200/edbk_404770
BibTeX
@article{Gouda2023,
author = {Gouda, Mohamed A and Subbiah, Vivek},
title = {Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors},
journal = {American Society of Clinical Oncology Educational Book},
year = {2023},
doi = {10.1200/edbk_404770}
}
EUVIMED